Skip to content

Propofol-butorphanol Anesthesia During Uterine Curettage

Propofol-butorphanol Combined Anesthesia During Uterine Curettage on Abortion

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00795314
Acronym
PABADUC
Enrollment
150
Registered
2008-11-21
Start date
2008-11-30
Completion date
2009-07-31
Last updated
2009-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abortion, Curettage

Keywords

Opioids, General anesthesia

Brief summary

Uterine curettage is usually performed under the anesthesia of propofol-fentanyl or para-cervical block,of which generally has significant incidence of respiratory depression which increases the demand on intraoperative monitoring, or has unavoidable insufficient blockade which results in intraoperative suffering of pain. Butorphanol is an analgesic with combined effects on mu and kappa opioid receptors leading to a role as analgesia and sedation. The investigators hypothesized that combined propofol with butorphanol during uterine curettage would produce optimal effectiveness of these two drugs by adding sedative and analgesic effects together. In addition, it would decrease the intraoperative consumption of propofol without increase the incidence of side effects. Furthermore, such combination would alleviate postoperative pain.

Interventions

DRUGFentanyl Citrate

Combined anesthesia with propofol (2-2.5mg/kg) and fentanyl (5 μg)

Combined anesthesia with propofol (2-2.5 mg/kg) and butorphanol (1mg)

Sponsors

Nanjing Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
19 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* ASA status I-II; * Performing abortion operation (medical- or drug-induced); * Requiring painless abortion;

Exclusion criteria

* \< 19yrs, and \>= 45yrs; * History of central active drugs administration; * Drug abuse; * Hypertension; * Diabetes; * Any other chronic diseases; * Allergy to the study drugs; * Habit of over-volume alcohol drinking; * Records of history of centrally active drug use and psychiatry; * Any organic disorders.

Design outcomes

Primary

MeasureTime frame
Intraoperative awarenessDuring the whole process of anesthesia

Secondary

MeasureTime frame
Bispectral Index (BIS) valueDuring the whole process of anesthesia
Anesthetic consumptionsFrom the start of operation to the end of surgical procedures
Postoperative painSince the end of the operation to 48 h follow-up.
Postoperative bleedingSince the end of operation to 48 h follow-up

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026